Search
Vivani Medical Inc
VANIAdd to Watchlist
1.260USD
+0.030+2.44%
Close 07/02, 13:00（ET）Quotes delayed by 15 min
106.66MMarket Cap
LossP/E TTM
View Detailed Chart
TradingKey 图表Intraday
1m
30m
1h
D
W
M
D
Today
+2.44%
5 Days
+10.53%
1 Month
-3.08%
6 Months
-0.79%
Year to Date
+2.44%
1 Year
-0.79%
Key Figures
1.240Open
1.350High
1.34MVolume
LossP/E TTM
LossP/E Dynamic
--Dividend TTM
1.58%Turnover Ratio
1.230Prev. Close
1.230Low
1.31MTurnover
LossP/E Static
5.59P/B
0.00%Div Yield TTM
-69.63%ROA
1.92052wk High
17.13Volume Ratio
-23.49MNet Profit
84.65MShares
-0.4035EPS TTM
2.31Beta
-176.41%ROE
0.92352wk Low
9.75%Amplitude
--Gross Margin
106.66MMarket Cap
-0.93Reward/Risk
4.22%Risk Rate
TradingKey Stock Score of Vivani Medical Inc
Currency: USD Updated: 2026-07-01Key Insights
Vivani Medical Inc's fundamentals are relatively very healthy, and its growth potential is significant.Its valuation is considered fairly valued, ranking 112 out of 204 in the Healthcare Equipment & Supplies industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 4.62.In the medium term, the stock price is expected to trend up.Despite an average stock market performance over the past month, the company shows strong technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Vivani Medical Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Neutral
Vivani Medical Inc Highlights
StrengthsRisks
Vivani Medical, Inc. is a clinical-stage biopharmaceutical company, developing miniature, ultra-long-acting drug implants. Leveraging its NanoPortal platform, it develops biopharmaceutical implants designed to deliver drug molecules steadily over extended periods of time with the goal of guaranteeing adherence, and to improve patient tolerance to their medication. Its lead program, NPM-115, is a six-month, subdermal, GLP-1 (exenatide) implant under development for chronic weight management in overweight individuals. Its pipeline includes NPM-139 (semaglutide implant), which is also under development for chronic weight management. NPM-119 refers to its six-month, subdermal, GLP-1 (exenatide) implant under development for the treatment of type 2 diabetes. These NanoPortal implants are designed to provide patients with the opportunity to realize the benefit of their medication by avoiding the challenges associated with the daily or weekly administration of orals and injectables.
Fairly Valued
The company’s latest PE is -3.05, at a medium 3-year percentile range.
Institutional Buying
The latest institutional holdings are 7.56M shares, increasing 31.07% quarter-over-quarter.
Held by Bill Nygren | OAKMX
Star Investor Bill Nygren | OAKMX holds 333.05K shares of this stock.
Lower Market Activity
The company has less investor interest, with a 20-day turnover ratio of -0.06.
Analyst Rating
Based on
4
analysts
Buy
Current Rating
4.625
Target Price
+282.23%
Upside Space
Vivani Medical Inc News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Vivani Medical Inc Info
Vivani Medical, Inc. is a clinical-stage biopharmaceutical company, developing miniature, ultra-long-acting drug implants. Leveraging its NanoPortal platform, it develops biopharmaceutical implants designed to deliver drug molecules steadily over extended periods of time with the goal of guaranteeing adherence, and to improve patient tolerance to their medication. Its lead program, NPM-115, is a six-month, subdermal, GLP-1 (exenatide) implant under development for chronic weight management in overweight individuals. Its pipeline includes NPM-139 (semaglutide implant), which is also under development for chronic weight management. NPM-119 refers to its six-month, subdermal, GLP-1 (exenatide) implant under development for the treatment of type 2 diabetes. These NanoPortal implants are designed to provide patients with the opportunity to realize the benefit of their medication by avoiding the challenges associated with the daily or weekly administration of orals and injectables.
Ticker SymbolVANI
CompanyVivani Medical Inc
CEOMendelsohn (Adam)
Websitehttps://vivani.com/
Related Instruments
-0.37%
+1.91%
+3.48%
+5.87%
+2.10%
-0.10%
+4.19%
+5.03%
+4.30%
+0.25%
+3.65%
+4.74%
+2.79%
+2.59%
-3.06%
+3.76%
+3.40%
+1.10%
-2.09%
+3.50%Popular Instruments
53074.700
+232.200 (+0.44%)
29433.600
+122.200 (+0.42%)
7499.800
+28.300 (+0.38%)
14809.000
+6.000 (+0.04%)
69024.000
+876.000 (+1.28%)
6372.200
+19.400 (+0.30%)
68.363
+0.019 (+0.03%)
308.630
+14.250 (+4.84%)
194.830
-2.750 (-1.39%)
4187.850
+65.940 (+1.60%)
FAQs
What is the current price of Vivani Medical Inc (VANI)?
The current price of Vivani Medical Inc (VANI) is 1.26.
What is the symbol of Vivani Medical Inc?
The ticker symbol of Vivani Medical Inc is VANI.
What is the 52-week high of Vivani Medical Inc?
The 52-week high of Vivani Medical Inc is 1.92.
What is the 52-week low of Vivani Medical Inc?
The 52-week low of Vivani Medical Inc is 0.92.
What is the market capitalization of Vivani Medical Inc?
The market capitalization of Vivani Medical Inc is 106.66M.
Is Vivani Medical Inc (VANI) currently rated as Buy, Hold, or Sell?
According to analysts, Vivani Medical Inc (VANI) has an overall rating of Buy, with a price target of 4.62.
What is the Earnings Per Share (EPS TTM) of Vivani Medical Inc (VANI)?
The Earnings Per Share (EPS TTM) of Vivani Medical Inc (VANI) is -0.43.